anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide a compound and/or composition capable of modulating protein phosphatase-2A (PP2A) activity.SOLUTION: Specified compounds expressed by formulae mentioned in the present specification (e.g., formulae I, Ia, Ib, Ic, Id, Ie, If, Ig, and/or Ih) as well as classes and subclasses thereof mentioned in the present specification are capable of modulating PP2A activity. Compounds capable of modulating the PP2A activity can potentially be useful for treating various diseases and/or disorders instantiated, for example, by neurodegeneration, diabetes, and metabolic disorders. In some embodiments, the compounds directly modulate the PP2A activity. In other embodiments, the compounds indirectly modulate the PP2A activity. In some other embodiments, the compounds modulate PP2A methylated states. In still other embodiments, the compounds modulate activity of PP2A methyltransferase.
Hepatic adverse events have been reported in patients receiving a dolutegravir-containing regimen [see Adverse Reactions (6.1, 6.2)]. Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of TRIUMEQ or TRIUMEQ PD [see Adverse Reactions (6.1)]. In some cases, the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation particularly in the setting where anti-hepatitis therapy was withdrawn. Cases of hepatic toxicity, including elevated serum liver biochemistries, hepatitis, and acute liver failure, have also been reported in patients, including pediatric patients receiving a dolutegravir-containing regimen who had no pre-existing hepatic disease or other identifiable risk factors. Drug-induced liver injury leading to liver transplant has been reported with TRIUMEQ. Monitoring for hepatotoxicity is recommended.
Sodium chloride in water dissociates to provide sodium (Na +) and chloride (Cl‾) ions. These ions are normal constituents of the body fluids (principally extracellular) and are essential for maintaining electrolyte balance. 

The distribution and excretion of sodium (Na +) and chloride (Cl‾) are largely under the control of the kidney which maintains a balance between intake and output. 

The small volume of fluid and amount of sodium chloride provided by 0.9% Sodium Chloride Injection, USP when used only as an isotonic vehicle for parenteral injection of drugs, is unlikely to exert a significant effect on fluid and electrolyte balance except possibly in neonates and very small infants.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).

Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na +) plays a major role in maintaining physiologic equilibrium.
DN for the MTrPs will be performed over the identified trigger points locations at a suitable angle. The needles of suitable length and thickness (30-mm), depending on the depth of the MTrPs location inserted into the shoulder girdle muscles to deactivate the active MTrPs. Subsequently, the inserted needles moved to-and-fro direction to elicit the local twitch responses, which further reaffirms the ideal placement of needle into the MTrPs. After the twitch response obtained, the dry needles were kept within the muscles approximately for 10 minutes. Dry needling was performed subscapularis, latissimus dorsi, supraspinatus, deltoid, teres minor.
PURPOSE: Provided is a pharmaceutical preparation containing a hydrophilic gelatinizing agent, water and a compound of formula (I), which is suitable for treatment and prophylaxis of skin mycoses. CONSTITUTION: Provided is a hydrophilic gelatinizing agent, water, compounds of formula 1 or pharmaceutical preparation comprising physiologically acceptable salt thereof. In formula 1, R¬1, R¬2 and R¬3 are identical or different each other, and hydrogen atom or alkyl having 1-4 carbons. R¬4 is radical having 6-9 saturated hydrocarbons. In preferable pharmaceutical preparation, R¬4 is saturated hydrocarbon having 6-9 carbon, one of R¬1 and R¬3 is hydrogen atom the other one is hydrogen atom or methyl or ethyl, R¬2 is alkyl radical having 1-2 carbon. The most preferable pharmaceutical preparation comprises a compound of formula 1 having cyclic radical at R¬4 in particular, R¬4 is cyclohexyl radical or -CH2-CH(CH3)-CH2-C(CH3)3.
The present invention relates to low immunogenic gene modification immune globulin and an application thereof. The present invention aims to provide low immunogenic immune globulin which can keep original specificity and affinity. The low immunogenic immune globulin contains the sequence of a variable region of light chain of mother antibodies and/or the sequence of a variable region of heavy chain of mother antibodies. The low immunogenic immune globulin is characterized in that in the variable region of light chain or heavy chain of the immune globulin, at least one mother FR secondary zone sequence is replaced or displaced by a corresponding FR secondary zone which has a source different from mother antibodies; the FR secondary zone sequence is FR1, FR2, FR3 or FR4. The immune globulin whose genes are recombined or framework is displaced is supposed to have FR secondary zone sequences from at least two different immune globulin chains. Antibodies which are composed of the immune globulin whose genes are recombined or framework is displaced can keep the specificity and the affinity of mother antibodies within three times.
Physical exercise has been shown to increase brain volume and improve cognition in randomized trials of non-demented elderly. Although greater social engagement was found to reduce dementia risk in observational studies, randomized trials of social interventions have not been reported. A representative sample of 120 elderly from Shanghai, China was randomized to four groups (Tai Chi, Walking, Social Interaction, No Intervention) for 40 weeks. Two MRI's were obtained, one before the intervention period, the other after. A neuropsychological battery was administered at baseline, 20 weeks and 40 weeks. Comparison of changes in brain volumes in intervention groups with the No Intervention group were assessed by t-tests. Time-intervention group interactions for neuropsychological measures were evaluated with repeated-measures mixed models.
A bovine rhinotracheitis vaccine is prepared by attenuating infectious bovine rhinotracheitis virus by passing the virus a plurality of times in a culture of lamb tissue cells particularly lamb renal cells.  At least five, preferably 25, and up to 125 serial passages through the lamb cells are made.  The Ithaca strain of infectious bovine rhinotracheitis virus is used to inoculate a trypsinized lamb embryo renal tissue culture in an aqueous mixture consisting of 80% Earle's salt solution, 10% inactivated calf serum and 10% lactalbumin hydrolysate.  After 72 hours, the virus is transferred to a second culture tube and the process is repeated for the desired number of passages.  The supernatant fluid from a number of culture vessels is pooled, assayed for virus content and diluted with a stabilizing menstruum to give a virus content of 50,000 T.C.I.D. 50's per mil.  The product may be freeze dried. Specification 846,755 is referred to.
In the event of overdose, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. Desloratadine and 3-hydroxydesloratadine are not eliminated by hemodialysis.

Information regarding acute overdosage is limited to experience from post-marketing adverse event reports and from clinical trials conducted during the development of the Desloratadine product. In a dose-ranging trial, at doses of 10 mg and 20 mg/day somnolence was reported.

In another study, no clinically relevant adverse events were reported in normal male and female volunteers who were given single daily doses of Desloratadine 45 mg for 10 days [see Clinical Pharmacology (12.2)].
Empathic concern and personal distress are common vicarious emotional responses that arise when witnessing someone else's pain. However, the influence of perceived similarity on these responses remains unclear. In this study, we examined how perceived similarity with an injured target impacts vicarious emotional responses. A total of 87 participants watched a video of an athlete in pain preceded by a clip describing the athlete's trajectory, which indicated either high, moderate, or low similarity to the participants. Emotional self-reports, facial expressions, gaze behavior, and pupil diameter were measured as indicators of the participants' emotional responses. Participants in the moderate- and high-similarity groups exhibited greater empathic concern, as evidenced by their display of more sadness compared with those in the low-similarity group. Furthermore, those in the moderate-similarity group exhibited less avoidance by displaying reduced disgust, indicating lower personal distress compared with those in the low-similarity condition. Nevertheless, the high-similarity group displayed just as much disgust as the low-similarity group. These findings suggest that perceived similarity enhances empathic concern to others' suffering, but that high similarity can also lead to personal distress. Future studies on empathy should explore distinct vicarious states using multimodal measurements to further advance our understanding of these processes.
Patients are assigned to one of two groups. Serum 25(OH)D level will be determined as \<12 ng/ml group 1, group 2 with ≥12 ng/ml. ASA I-II children aged 2-10 years who will undergo adenoidectomy and/or tonsillectomy surgery under general anesthesia will be included in the study. In the operating room, the patient will monitored using electrocardiography, pulse oximetry, noninvasive blood pressure measurements, capnography. Under anesthesia, blood samples were taken for serum 25(OH)D levels. After extubation, patients will be taken to the recovery room. Delirium will be evaluated using the PAED (Pediatric Anesthesia Emergence Delirium) scale at 10-minute intervals in the recovery unit. In our study, 25(OH)D level was measured.
Lanthanum Carbonate: initial dose 500 mg TID with meals, titrated at monthly intervals in 500 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis (serum phosphorus, PTH or TRP). Normality for this marker will be defined as serum phosphorus of 2.6-4.6 mg/dl, PTH of 10-65pg/ml and TRP\>=80%.
In vitro methods for making a recombinant adenoviral genome, as well as kits for practicing the same and the recombinant adenovirus vectors produced thereby, are provided. In the subject methods, the subject genomes are prepared from first and second vectors. The first vector includes an adenoviral genome having an E region deletion and three different, non-adenoviral restriction endonuclease sites located in the E region. The second vector is a shuttle vector and includes an insertion nucleic acid flanked by two of the three different non-adenoviral vectors present in the first vector. Cleavage products are prepared from the first and second vectors using the appropriate restriction endonucleases. The resultant cleavage products are then ligated to produce the subject recombinant adenovirus genome. The subject adenoviral genomes find use in a variety of application, including as vectors for use in a variety of applications, including gene therapy.
PCT No. PCT/AU96/00518 Sec. 371 Date Apr. 20, 1998 Sec. 102(e) Date Apr. 20, 1998 PCT Filed Aug. 14, 1996 PCT Pub. No. WO97/06826 PCT Pub. Date Feb. 27, 1997A method of delivering a nucleic acid molecule to a human cell which involves exposing to the cell a viral vector containing a DNA molecule including a nucleic acid sequence encoding the genome of an ovine adenovirus capable of infecting human cells or functionally equivalent nucleic acid sequence or portion thereof and at least one nucleic acid sequence encoding a gene to be expressed in the cell, such that the vector infects the cell and the infected cell expresses the gene.
Protein kinase A (PKA) plays an important role in cellular life activities. Recently, PKA was found to bind to the inhibitor of nuclear factor-kappaB (IκB), a key protein in the nuclear factor-kappaB (NF-κB) pathway, to form a complex involved in the regulation of inflammatory response. However, the role of PKA in the anti-inflammatory of goose fatty liver is still unclear. A total of 14 healthy 70-d-old male Lander geese were randomly divided into a control group and an overfeeding group. Inflammation level was analyzed by histopathological method in the liver. The mRNA and protein abundance of PKA and tumor necrosis factor-alpha (TNFα), as well as the ubiquitination level of PKA, were detected. Moreover, goose primary hepatocytes were cotreated with glucose, harringtonine, and carbobenzoxy-l-leucyl-l-leucyl-l-leucinal (MG132). Finally, the co-immunoprecipitated samples of PKA from the control and overfeeding group were used for protein mass spectrometry. The results showed that no difference in PKA mRNA expression was observed (P > 0.05), while the PKA protein level in the overfed group was significantly reduced (P < 0.05) when compared with the control group. The ubiquitination level of PKA was higher than that of the control group in fatty liver. The mRNA expression of PKA was elevated but protein abundance was reduced in goose primary hepatocytes with 200 mmol/L glucose treatment (P < 0.05). The PKA protein abundance was dramatically reduced in hepatocytes treated with harringtonine (P < 0.01) when compared with the glucose-supplemented group. Nevertheless, MG132 tended to alleviate the inhibitory effect of harringtonine on PKA protein abundance (P = 0.081). There was no significant difference in TNFα protein level among glucose-treated groups and control (P > 0.05). Protein mass spectrometry analysis showed that 29 and 76 interacting proteins of PKA were screened in goose normal and fatty liver, respectively. Validation showed that PKA interacted with the E3 ubiquitination ligases ring finger protein 135 (RNF135) and potassium channel modulatory factor 1 (KCMF1). In summary, glucose may inhibit the inflammatory response in goose fatty liver by increasing the ubiquitination level of PKA. Additionally, RNF135 and KCMF1 may be involved in the regulation of PKA ubiquitination level as E3 ubiquitination ligases.
Embodiments of the present disclosure concerns methods and compositions related to treatment using a CRISPR/Cas9/targeting antibody/gene targeting small guide RNA(sgRNA) fusion protein/ribonucleotide complex. The targeting of a polynucleotide of interest, such as a gene, may be effective to eradicate tumors in mammals. In some cases, sgRNA ribonucleotides with sequences designed to target any gene or genomic region are contemplated. In some embodiments, the targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR-based gene modification in vivo obviating the need for adoptive cell therapy. In some cases, substitutions of the CD25 targeting antibody is replaced with another antibody to recognize other cell surface antigens. In some cases, sgRNA ribonucleotides with sequences designed to target any gene or genomic region are described.
The invention discloses polypeptide CJ128 resistant to HIV-1 activity and application of the polypeptide CJ128. The polypeptide is named as the polypeptide CJ128 and is polypeptide shown in the sequence 1 of a sequence table. The invention further relates to the application of the polypeptide CJ128 in preparing an HIV-resistant drug. The invention further relates to the HIV-resistant drug. The active component of the HIV-resistant drug is the polypeptide CJ128. The polypeptide CJ128 has significant value for treating AIDS.
Patients with LARC, receiving neoadjuvant chemoradiotherapy (CRT) are followed by at least 4 multiparametric MRI-scans (diffusion weighted imaging and hypoxia-sensitive sequences) as well as repeated blood samples in order to analyse circulating tumour cells (CTCs). A standard pelvis radiotherapy (RT, 5040 cGy) will be performed in combination with a 5-Fluorouracil / Oxaliplatin regimen in all patients (planned: N = 50), succeeded by consolidation CTx (FOLFOX4) if feasible. Additional histologic markers, such as tumour-infiltrating lymphocytes (TILs) or PD-L1 status will be analysed before and after CRT. Resection is standard after completion of preoperative treatment. In case of complete regression and patient's request, a non-operative management ("watch and wait") is offered alternatively. The primary endpoint is response, defined by tumor regression grading, secondary endpoints comprise longitudinal changes in MRI as well as in CTCs and TILs.
Clinical equipoise exists around the optimal time to start adjuvant endocrine therapy in patients who will receive post-operative radiotherapy for breast cancer. Patients receive either concurrent or sequential endocrine and radiation therapy, where concurrent therapy consists of endocrine therapy started before, with or during radiotherapy, while sequential treatment is defined as endocrine therapy starting after the completion of radiotherapy. A recent survey of Canadian oncologists showed that the main reason for prescribing sequential endocrine therapy was a concern that concurrent endocrine therapy and radiotherapy would worsen the toxicity of endocrine treatment. This is despite the absence of any clinical trial evidence to support this. Indeed, a recent systematic review by our group was unable to confirm or refute whether increased toxicities, related to the timing of endocrine therapy and radiotherapy actually exist in clinical practice. The investigators are therefore proposing a pragmatic randomised trial to assess whether or not concurrent endocrine therapy and radiotherapy worsens endocrine treatment-related symptoms in an era of modern endocrine and radiation therapy.
INTRODUCTION: The impact of chemoimmunotherapy (CIT) on immunoglobulin (Ig) quantities in patients with chronic lymphocytic leukemia (CLL) has not been extensively studied.
METHODS: We analyzed Ig levels in 45 stable patients with indolent CLL (without indication for treatment) and 87 patients with progressive disease before first-line treatment. Fifty-five patients were evaluated again after the treatment with CIT.
RESULTS: We observed significantly lower levels of all Ig classes and subclasses in patients with progressive disease compared to patients with indolent disease. After treatment, median IgA increased from 0.59 g/L to 0.74 g/L (p = 0.0031). In stable patients, lower IgA2 was associated with shorter time to first treatment, although it did not reach statistical significance (p = 0.056). Shorter overall survival was observed in patients with progressive disease and lower IgG2 (p = 0.043). Surprisingly, among the patients with progressive CLL, unmutated IGHV genes were associated with higher levels of IgG, IgG1 and IgM, while TP53 mutation and/or 17p deletion were associated with higher levels of IgA and IgA1.
CONCLUSIONS: CIT may lead to increase in IgA levels. Hypogammaglobulinemia is more common in patients with progressive CLL and unmutated IGHV or TP53 dysfunction.
Conventional rehabilitation (stretching, strengthening, balance) plus dual task exercise training (simple math during active stretching, carrying the ball without dropping child while on the balance pad) will be applied 3 days a week for 12 weeks. Interventions will be implemented individually. Patients will be evaluated before and 12 weeks after the interventions.
FIELD: medical cosmetics; applicable as alternative method for operative elimination of defects of face and neck. SUBSTANCE: offered is new, special method of vibration effect including quick loop-shaped rubbing and urging-on motions with a rate of 200-250 motions per minute (that differs from commonly used frequencies by 3-3.5 times) allows cleaning of capillaries of integument, introduction into cell the required nutrient, restoration of flexibility of muscles and ligaments of face and neck soft tissues. Massage means in large quantity and citric acid contained in them being natural solvents of neutral fats promotes their dissolving and withdrawal. All these lead to reduction of panniculus adiposus to possible minimum and eliminates excessive skin not by cutting off, but due to skin natural tightening. Besides, considerable reduction of face muscle mass takes place that leads to gradual reformation of face features. i.e., partial rejuvenascence. Massage is effected not by massage lines but with consideration of anatomo-physiological location of muscles and ligaments, the total number of motions given to treatment of each muscle up to 4000 that exceeds the commonly used number by 150 times. EFFECT: higher efficiency.
Ferroptosis plays an important role in the early stage of myocardial ischemia/reperfusion (MI/R) injury, which is closely associated with the antioxidant damage of mitochondrial cysteine (Cys)/glutathione (GSH)/glutathione peroxidase 4 (GPX4) axis. Visualization of Cys and GSH in mitochondria is meaningful to value ferroptosis and further contributes to understanding and preventing MI/R injury. Herein a mitochondria-targetable thiols fluorescent probe (MTTP) was designed and synthesized based on sulfonyl benzoxadiazole (SBD) chromophore with a triphenylphosphine unit as the mitochondria-targeted functional group. Cys and GSH can be differentiated by MTTP with two distinguishable emission bands (583 nm and 520 nm) through the controllable aromatic substitution-rearrangement reaction. Importantly, MTTP is capable of monitoring ferroptosis and its inhibition by measuring mitochondrial Cys and GSH. MTTP was also employed to non-invasively detect ferroptosis during oxygen and glucose deprivation/reoxygenation (OGD/R)-induced MI/R injury in H9C2 cells. In a word, MTTP provides a visual tool that can simultaneously detect Cys and GSH to monitor ferroptosis processes during MI/R injury, which helps for more deeper understanding of the role of ferroptosis in MI/R injury-related diseases.
PURPOSE: To obtain a plastic molding having high transparency and refreshingness by dissolving menthol or methyl salicylate in a specific monomer or a specified oligomer, polymerizing the monomer or oligomer at a relatively low temperature and curing the resultant polymer. CONSTITUTION: This plastic molding contains components (A) to (C). (A) 30-99wt.% compound having (meth)acryloyl group or an allyl carbonate-based compound, (B) 1-22wt.% L-menthol or methyl salicylate and (C) 0.001-5wt.% polymerization initiator. The molding is obtained by uniformly dissolving a composition containing the components (A) to (C), casting the resultant solution into a forming mold, then polymerizing and curing the composition with energy such as heat or active energy rays. The resultant molding can be used as ornaments such as a personal ornament or an ornament for the alcove or utilized as various utility articles utilizing the refreshingness or a substitute comparable to crystal glass. When the molding is used as a sustained release material, it has semipermanent aromaticity.
Up to 6 subjects will be enrolled (defined as receiving malaria challenge) later in the trial to serve as challenge controls. Additional subjects may be recruited as alternates to ensure that 6 control subjects undergo the challenge. Any alternates not challenged will be released from the study at day of challenge.